Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

Siddharth Singh; Darrell S. Pardi

doi:10.1016/j.gtc.2014.05.008

Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

Siddharth Singh, Darrell S. Pardi

Gastroenterology and Hepatology

Research output: Contribution to journal › Review article › peer-review

28 Scopus citations

Abstract

Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

Original language	English (US)
Pages (from-to)	457-478
Number of pages	22
Journal	Gastroenterology Clinics of North America
Volume	43
Issue number	3
DOIs	https://doi.org/10.1016/j.gtc.2014.05.008
State	Published - Sep 2014

Keywords

Adalimumab
Anti-tumor necrosis factor
Certolizumab pegol
Crohn disease
Infliximab

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.gtc.2014.05.008

Cite this

@article{d865dea380964caea3e68c3350b9ac3a,

title = "Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease",

abstract = "Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.",

keywords = "Adalimumab, Anti-tumor necrosis factor, Certolizumab pegol, Crohn disease, Infliximab",

author = "Siddharth Singh and Pardi, {Darrell S.}",

year = "2014",

month = sep,

doi = "10.1016/j.gtc.2014.05.008",

language = "English (US)",

volume = "43",

pages = "457--478",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

AU - Singh, Siddharth

AU - Pardi, Darrell S.

PY - 2014/9

Y1 - 2014/9

N2 - Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

AB - Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

KW - Adalimumab

KW - Anti-tumor necrosis factor

KW - Certolizumab pegol

KW - Crohn disease

KW - Infliximab

UR - http://www.scopus.com/inward/record.url?scp=84905723625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905723625&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2014.05.008

DO - 10.1016/j.gtc.2014.05.008

M3 - Review article

C2 - 25110253

AN - SCOPUS:84905723625

SN - 0889-8553

VL - 43

SP - 457

EP - 478

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

IS - 3

ER -

Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this